Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

B-cell lymphomas


Other Names for this Disease

  • Lymphoma, B-Cell
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied B-cell lymphomas. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Tositumomab and iodine I 131 tositumomab
Trade Name
(Manufacturer Name)
Bexxar®
(GlaxoSmithKline)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Rituximab
Trade Name
(Manufacturer Name)
Rituxan® (injection)
(Genentech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of non-Hodgkin's B-cell lymphoma.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Ibritumomab tiuxetan
Trade Name
(Manufacturer Name)
Zevalin
(Cell Therapeutics, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin?s lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Lymphoma, B-Cell
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.